Table 1c.
Antidepressants in Treatment of Extrapyramidal Symptoms
| Antidepressant Group | Author(s) | Year | Antidepressant |
Dose,
mg |
Antipsychotic | N |
Duration,
wk |
Efficacy Measures | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| SSRIs | Goff et al. | 1995 | Fluoxetine | 20 | Depot FGAs | 41 | 6 | n/r | No change in either group. |
| Arango et al. | 2000 | Fluoxetine | 20–40 | Various FGAs | 32 | 8 | MIMS | No change in either group. | |
| Bustillo et al.* | 2003 | Fluoxetine | 60 | Olanzapine | 31 | 8 | SAS, BAS, AIMS | No change in either group. | |
| Lee et al. | 1998 | Sertraline | 50 | Haloperidol | 36 | 8 | SAS | No change in either group. | |
| Mulholand et al.* | 2003 | Sertraline | 50 | Various FGAs, risperidone | 26 | 8 | ESRS, BAS | No change in sertraline group, worsening of ESRS scores in placebo group. | |
| Jockers et al. | 2005 | Paroxetine | 30 | Various FGAs and SGAs | 29 | 12 | SAS, BAS, AIMS | No change in either group. | |
| Iancu et al. | 2010 | Escitalopram | 20 | Various FGAs and SGAs | 38 | 10 | AIMS | No change in either group. | |
| NRI | Schutz and Berk | 2001 | Reboxetine | 8 | Haloperidol | 30 | 8 | SAS | No change in either group. |
| Poyurovski et al.* | 2003 | Reboxetine | 4 | Olanzapine | 26 | 6 | BAS, SAS | SAS scores decreased in both groups with no between-group difference in observed change. | |
| Receptor-blocking antidepressants | Hayashi et al. | 1997 | Trazodone | 50–200 | n/r | 39 | 5 | AIMS | Improvement in trazodone group. |
| Stryjer et al. | 2010 | Trazodone | 100 | n/r | 13 | 1 | SAS, BAS | Between group differences on the BAS scores in favour of trazodone. No changes on SAS scores in either group. | |
| Hayashi et al. | 1997 | Mianserin | 20–60 | n/r | 39 | 5 | AIMS | No change in either group. | |
| Poyurovski et al. | 2003 | Mianserin | 15 | Various FGAs | 30 | 4 | BAS, SAS, AIMS | No change in either group. | |
| Berk et al. | 2001 | Mirtazapine | 30 | Haloperidol | 30 | 6 | SAS | No change in either group. | |
| Joffe et al.* | 2009 | Mirtazapine | 30 | Various FGAs | 39 | 6 | SAS | Improvement on the SAS scores in mirtazapine group. No between group differences. | |
| Berk et al. | 2009 | Mirtazapine | 30 | Various SGAs | 40 | 6 | SAS | No change in either group. | |
| Abbasi et al. | 2010 | Mirtazapine | 30 | Risperidone | 40 | 8 | ESRS | No change in either group. | |
| Lee et al. | 2011 | Mirtazapine | 15–30 | Risperidone | 21 | 8 | SAS, BAS | No between group differences on either measure. | |
| Wynchank and Berk | 2003 | Nefazodone | 100 | Haloperidol | 49 | 1 | SAS, BAS, AIMS | Improvement on the SAS in nefazodone group. No changes on the BAS or AIMS in either group. |